Over- and underestimation of hepatic steatosis by CAP are driven by distinct clinical predictors. Our risk algorithm reliably identifies a "concordant zone" where CAP can be used confidently, while guiding selective MRI-PDFF confirmation for patients at high risk of discordance, thereby optimizing non-invasive assessment strategies.
Kim et al. (Fri,) studied this question.